Tissue Typing Compartment, Department for laboratory testing, Institute for Blood Transfusion of Vojvodina, Hajduk Veljkova 9a, 21000, Novi Sad, Serbia
Tissue Typing Compartment, Department for laboratory testing, Institute for Blood Transfusion of Vojvodina, Hajduk Veljkova 9a, 21000, Novi Sad, Serbia
References
[1] Slavcev A. Donor-specific antibodies and kidney transplant rejection. Annals of Transplantation 2003; 8(3):12–15
[2] Muro M, Ljorenze S, Marin L, Moya-Quiles MR, et al. Acute vascular rejection mediated by HLA antibodies in a cadaveric kidney recipient: discrepancies between FlowPRATM, ELISA and CDC vs luminex screening. Nephrology Dialysis Transplantation 2005;20:223–226 http://dx.doi.org/10.1093/ndt/gfh527[Crossref]
[3] Amico P, Honger G, Mayr M, Schaub S. Detection of HLA antibodies prior renal transplantation: prospects and limitations of new assays. Swiss Medical Weekly 2008; 138(33–34):472–476
[4] Pelletier RP, Adams PW, Hennessy PK, Orosz CG. Comparison of crossmatch results obtained by ELISA, flow cytometry, and conventional methodologies. Humman Immunology 1999; 60(9):855–861 http://dx.doi.org/10.1016/S0198-8859(99)00072-5[Crossref]
[5] Goggins R, Geiselhart L. Antibody screening beyond tears. ASHI Qarterly. Second Quarter 2003:70–72
[6] Moise A, Nedelcu D, Toader A, Sora M, Tica A, Ferastraoaru DE, Constantinescu I. Cytotoxic antibodies - valuable prognostic factor for long term kidney allograft survival. Journal of Medicine and Life 2010; 3(4):390–395
[7] Lucas DP, Paparounis ML, Myers L, Hart JM, et al. Detection of HLA class I-specific antibodies by the QuickScreen Enzyme-Linked Immunosorbent Assay. Clinical and Diagnostic Laboratory Immunology 1997; 4(3):252–257
[8] Tait BD, Hudson F, Cantwell L, Brewin G, et al. Luminex technology for HLA antibody detection in organ transplantation. Nephrology 2009; 14:247–254 http://dx.doi.org/10.1111/j.1440-1797.2008.01074.x[Crossref][WoS]
[9] Minucci PB, Grimaldi V, Casamassimi A, Cacciatore F, et al. Methodologies for Anti-HLA Antibody Screening in Patients Awaiting Kidney Transplant: A Comparative Study. Experimental and Clinical Transplantation 2011; 9(6):381–386
[10] Lefaucheur C, Loupy A, Hill GS, Andrade J, et al. Preexisting Donor-Specific HLA Antibodies Predict Outcome in Kidney Transplantation. Journal of the American Society of Nephrology 2010;21:1398–1406 http://dx.doi.org/10.1681/ASN.2009101065[Crossref]
[11] Altermann WW, Seliger B, Sel S, Wendt D, et al. Comparison of the established standard complement-dependent cytotoxicity and flow cytometric crossmatch assays with a novel ELISA-based HLA crossmatch procedure. Histology and Histopathology. 2006; 21:1115–1124
[12] Schlaf G, Pollok-Kopp B, Manzke T, Schurat O et al. Novel solid phase-based ELISA assays contribute to an improved detection of anti-HLA antibodies and to an increased reliability of pre- and posttransplant crossmatching. Nephrology Dialysis Transplantation. 2010; 3:527–538
[13] Puttarajappa C, Shapiro R, Tan HP. Antibody-Mediated Rejection in Kidney Transplantation: A Review. Journal of Transplantation. 2012:193724
[14] Kissmeyer-Nielsen F, Olsen S, Petersen VP, Fjeldborg O. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet 1966; 2(7465):662–665. http://dx.doi.org/10.1016/S0140-6736(66)92829-7[Crossref]
[15] Kao KJ, Scornik JC, Small SJ. Enzyme-linked immunoassay for anti-HLA antobodies - an alternative to panel studies by lymphocytotoxicity. Transplantation 1993; 55(1):192–196 http://dx.doi.org/10.1097/00007890-199301000-00036[Crossref]
[16] Moore BA, Ploeger NA, DeGoey SR. HLA antibody screening: Comparison of a solid phase Enzyme-Linked Immunoassay with antiglobulin-augmented lymphocytotoxicity. Transplantation 1997; 64(11):1617–1620 http://dx.doi.org/10.1097/00007890-199712150-00023[Crossref]
[17] Braun WE. Laboratory and clinical management of the highly sensitized organ transplant recipient. Humman Immunology 1989; 26(4):245–260 http://dx.doi.org/10.1016/0198-8859(89)90003-7[Crossref]
[18] Kang E-S, Kim S-J, Choi KB, Chung KY. Continuous monitoring of donor specific anti-HLA antibody in kidney transplantation patients. The Journal of the Korean Society for Transplantation 2009; 23:227–232 http://dx.doi.org/10.4285/jkstn.2009.23.3.227[Crossref]
[19] Slavcev A, Lacha J, Sajdlova H, Vitko Š, et al. Characterisation of patient antibodies after kidney transplantation. Annals of Transplantation 2001; 6(2):12–15
[20] Tiercy JM, Cattin S, Pongratz G, Goumaz C, et al. A complementary strategy for pretransplant HLA antibody screening. Transplant Proceedings 2002; 34:850–851 http://dx.doi.org/10.1016/S0041-1345(02)02685-4[Crossref]
[21] Worthington JE, Langton A, Liggett H, Robson AJ, et al. A novel strategy for the detection and definition of HLA-specific antibodies in patients awaiting renal transplantation. Transplant International 1998; Suppl 1:S372–S376
[22] Fernandez-Fresnedo G, Pastor JM, Lopez-Hoyos M, Ruiz JC, et al. Relationship of donor-specific class-I anti-HLA antibodies detected by ELISA after kidney transplantation on the development of acute rejection and graft survival. Nephrology Dialysis Transplantation 2003; 18:990–995 http://dx.doi.org/10.1093/ndt/gfg068[Crossref]
[23] Arnold ML, Zacher T, Dechant M, Kalden JR, et al. Detection and specification of noncomplement binding anti-HLA alloantibodies. Humman Immunology 2004; 65(11):1288–1296 http://dx.doi.org/10.1016/j.humimm.2004.08.182[Crossref]
[24] Flesch B. Laboratory diagnostics of HLA antibodies. Laboratoriums Medizin 2003; 27(9–10):351–458 http://dx.doi.org/10.1046/j.1439-0477.2003.03067.x[Crossref]
[25] Jaramillo A, Smith MA, Phelan D, Sundaresan S, et al. Development of ELISA-detected anti-HLA antibodies precedes the development of bronchiolitis obliterans syndrome and correlates with progresive decline in pulmonary function after lung transplantation. Transplantation 1999; 67(8):1155–1161 http://dx.doi.org/10.1097/00007890-199904270-00012[Crossref]